Shandong Sinobioway Biomedicine Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 206.83 million compared to CNY 187.26 million a year ago. Revenue was CNY 209.17 million compared to CNY 187.64 million a year ago.

Net loss was CNY 53.76 million compared to net income of CNY 23.96 million a year ago. Basic loss per share from continuing operations was CNY 0.0815 compared to basic earnings per share from continuing operations of CNY 0.0363 a year ago. Diluted loss per share from continuing operations was CNY 0.0815 compared to diluted earnings per share from continuing operations of CNY 0.0363 a year ago.